Novavax, Inc. Financials

Market Capitalization $1.53 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-1.70
Forward PE	-59.69
Price to Sales TTM	$1.73
Price to Book MRQ	$-2.80
Enterprise to Revenue	1.00
Enterprise to EBITDA	-3.63

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	-32.18%
Operating Margin	-153.61%
Return on Assets TTM	-10.76%
Return on Equity TTM	76.03%

Income Statement

Revenue TTM	$885,193,024
Revenue per Share TTM	$6.19
Quarterly Revenue Growth	-54.80%
Gross Profit TTM	$115,461,000
EBITDA	$-243,246,000
Net Income to Common TTM	$-284,857,984
Diluted EPS TTM	$-2.18
Quarterly Earnings Growth YoY	283.03%

Balance Sheet

Total Cash MRQ	$909,531,008
Total Cash per Share MRQ	$5.68
Total Debt MRQ	$
Total Debt to Equity MRQ	-0.50
Current Ratio MRQ	0.94
Book Value per Share MRQ	$-3.29

Cash Flow

Operating Cash Flow TTM	$-90,881,000
Levered Free Cash Flow TTM	$-247,394,256

NVAX Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	160,184,992
Float Shares	143,383,190
Avg 10 Volume	4,356,780
Avg 30 Volume	None
Shares Short	36,917,946
Short Ratio	10.86
Short % of Shares	28.74%
% Held by Insiders	4.41%
% Held by Institutions	60.41%

Stock Price Summary

Beta	2.09
Fifty Two Week Low	$3.53
Fifty Two Week High	$23.86
Fifty Two Week Change	54.56%
Day 50 MA	$8.66
Day 200 MA	$10.91

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date	2019-05-10
Ex Dividend Date
Last Split Factor
Last Split Date	2019-05-10